Pathogens in Crohn's Disease: The Role of Adherent Invasive Escherichia coli
Gaetano Iaquinto,
Vera Rotondi Aufiero,
Giuseppe Mazzarella
et al.
Abstract:In Crohn's disease (CD), gut dysbiosis is marked by the prevalence of pathogenic bacterial species. Although several microbes have been reported as risk factors or causative agents of CD, it is not yet clear which is the real trigger of the disease. Thirty years ago, a new pathovar of <i>Escherichia coli </i>strain was isolated in the ileal mucosa of CD patients. This strain, called adherent invasive <i>E. coli</i> (AIEC), for its ability to invade the intestinal mucosa, could represent… Show more
“…In the last decades, several pathogens (Table 1) have been found to have a role in the pathogenesis of CD [8,9], but only E. coli [10][11][12][13] and Mycobacterium avium paratubercolosis (MAP) [14,15] have aroused interest due to their strong association with CD pathogenesis. In 1998, a new pathovar strain of E. coli, defined as adherent invasive E. coli (AIEC), was isolated from the ileal mucosa of CD patients, as that was assumed to be a potential etiological source of the disease [16].…”
Crohn’s disease (CD) is a multifactorial chronic disorder that involves a combination of factors, including genetics, immune response, and gut microbiota. Therapy includes salicylates, immunosuppressive agents, corticosteroids, and biologic drugs. International guidelines do not recommend the use of antibiotics for CD patients, except in the case of septic complications. Increasing evidence of the involvement of gut bacteria in this chronic disease supports the rationale for using antibiotics as the primary treatment for active CD. In recent decades, several pathogens have been reported to be involved in the development of CD, but only Escherichia coli (E. coli) and Mycobacterium avium paratubercolosis (MAP) have aroused interest due to their strong association with CD pathogenesis. Several meta-analyses have been published concerning antibiotic treatment for CD patients, but randomized trials testing antibiotic treatment against E. coli and MAP have not shown prolonged benefits and have generated conflicting results; several questions are still unresolved regarding trial design, antibiotic dosing, the formulation used, the treatment course, and the outcome measures. In this paper, we provide an overview and update of the trials testing antibiotic treatment for active CD patients, taking into account the role of pathogens, the mechanisms by which different antibiotics act on harmful pathogens, and antibiotic resistance. Finally, we also present new lines of study for the future regarding the use of antibiotics to treat patients with active CD.
“…In the last decades, several pathogens (Table 1) have been found to have a role in the pathogenesis of CD [8,9], but only E. coli [10][11][12][13] and Mycobacterium avium paratubercolosis (MAP) [14,15] have aroused interest due to their strong association with CD pathogenesis. In 1998, a new pathovar strain of E. coli, defined as adherent invasive E. coli (AIEC), was isolated from the ileal mucosa of CD patients, as that was assumed to be a potential etiological source of the disease [16].…”
Crohn’s disease (CD) is a multifactorial chronic disorder that involves a combination of factors, including genetics, immune response, and gut microbiota. Therapy includes salicylates, immunosuppressive agents, corticosteroids, and biologic drugs. International guidelines do not recommend the use of antibiotics for CD patients, except in the case of septic complications. Increasing evidence of the involvement of gut bacteria in this chronic disease supports the rationale for using antibiotics as the primary treatment for active CD. In recent decades, several pathogens have been reported to be involved in the development of CD, but only Escherichia coli (E. coli) and Mycobacterium avium paratubercolosis (MAP) have aroused interest due to their strong association with CD pathogenesis. Several meta-analyses have been published concerning antibiotic treatment for CD patients, but randomized trials testing antibiotic treatment against E. coli and MAP have not shown prolonged benefits and have generated conflicting results; several questions are still unresolved regarding trial design, antibiotic dosing, the formulation used, the treatment course, and the outcome measures. In this paper, we provide an overview and update of the trials testing antibiotic treatment for active CD patients, taking into account the role of pathogens, the mechanisms by which different antibiotics act on harmful pathogens, and antibiotic resistance. Finally, we also present new lines of study for the future regarding the use of antibiotics to treat patients with active CD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.